

HAEMODIALYSIS
IN
PRIVATE CENTRES

Stock and Flow

Death on Haemodialysis and Transfer to PD

Haemodialysis Patient Characteristics

Survival Analysis

Work related rehabilitation and quality of life

Haemodialysis practices

Dyslipidaemia in HD patients

Treatment of Renal Bone Disease

Management of Blood Pressure

Management of Anaemia

Nutritional status

Prevalence of anti-HCV antibodies and HbsAg


3.3: HAEMODIALYSIS IN PRIVATE CENTRES

3.3.1 STOCK AND FLOW

Table 3.3.01: Stock and Flow HD Patient, Private Centres 1995 – 2002

Year	1995	1996	1997	1998	1999	2000	2001	2002
New patients	122	174	192	284	400	515	500	470
Died	20	25	54	53	55	130	203	172
Transferred to PD	1	2	3	1	0	7	8	12
Transplanted	2	8	7	5	14	39	45	32
Lost to Follow up	0	2	3	2	2	5	18	14
Dialysing at 31 st December	319	465	595	823	1162	1507	1742	1990

Figure 3.3.01: Stock and Flow HD Patient, Private Centres 1995 – 2002



3.3.3 DEATH ON HAEMODIALYSIS, PRIVATE CENTRES

Table 3.3.04: HD Death Rate and Transfer to PD, Private Centres 1995 – 2002

	1995	1996	1997	1998	1999	2000	2001	2002
No. at risk	319	392	530	709	993	1335	1625	1866
Deaths	20	25	54	53	55	130	203	172
Death rate %	6	6	10	7	6	10	12	9
Transfer to PD	1	2	3	1	0	7	8	12
Transfer to PD rate %	0	1	1	0	0	1	0	1
All Losses	21	27	57	54	55	137	211	184
All Losses rate %	7	7	11	8	6	10	13	10

Figure 3.3.04: Death Rate on HD, Private Centres 1995 – 2002




Table 3.3.05: Causes of Death HD Patient, Private Centres 1999 – 2002

Causes of death	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
Cardiovascular	13	24	50	38	84	41	80	47
Died at home	14	25	34	26	68	33	48	28
Sepsis	8	15	12	9	15	7	10	6
GIT bleed	1	2	2	2	4	2	3	2
Cancer	1	2	3	2	3	1	4	2
Liver disease	2	4	2	2	2	1	2	1
Others	12	22	22	17	19	9	19	11
Unknown	4	7	5	4	6	3	6	3
Total	55	100	130	100	203	100	172	100

3.3.5 HAEMODIALYSIS PATIENTS' CHARACTERISTICS, PRIVATE CENTRES

Table 3.3.08: Age Distribution of Dialysis Patients, Private Centres 1999 – 2002

Year	1999	2000	2001	2002
New Dialysis patients	400	515	500	470
1-14 years	0	0	0	0
15-24 years	2	1	2	1
25-34 years	6	6	4	8
35-44 years	15	13	10	10
45-54 years	21	22	21	24
55-64 years	28	32	33	28
≥65 years	29	27	30	28
Dialysing at 31 st December	1162	1507	1742	1990
1-14 years	0	0	0	0
15-24 years	3	2	2	2
25-34 years	11	9	9	8
35-44 years	17	16	15	15
45-54 years	19	20	20	22
55-64 years	27	29	30	30
≥65 years	23	23	24	23

Table 3.3.09: Patients' Characteristics, Private Centres 1999 – 2002

Year	1999	2000	2001	2002
New Dialysis patients (No)	400	515	500	470
Mean age ± sd (years)	56 ± 14	56 ± 13	57 ± 13	55 ± 14
% Male	55	54	56	57
% Diabetic	47	53	52	54
% HbsAg+	4	4	3	3
% Anti-HCV+	11	6	4	3

3.3.6 SURVIVAL ANALYSIS, PRIVATE HD CENTRES

Table 3.3.10: HD Patient Survival, Private Centres 1997 – 2002

Year	1997			1998			1999		
Interval	% survival	SE	No	% survival	SE	No	% survival	SE	No
6	92	2	179	94	1	268	96	1	387
12	89	2	173	92	2	260	91	1	360
24	84	3	164	84	2	233	81	2	303
36	76	3	147	76	3	206	73	2	261
48	68	3	128	69	3	176			
60	60	4	103						

Year	2000			2001			2002		
Interval	% survival	SE	No	% survival	SE	No	% survival	SE	No
6	95	1	485	94	1	474	97	1	271
12	89	1	439	89	1	419			
24	81	2	374						

No. = number at risk SE = standard error

Figure 3.3.10: HD Patient Survival by year of entry, Private Centres





Table 3.3.11: HD Technique Survival, Private Centres

Year	1997			1998			1999		
Interval	% survival	SE	No	% survival	SE	No	% survival	SE	No
6	92	2	179	94	1	268	96	1	387
12	88	2	173	92	2	260	91	1	360
24	84	3	164	84	2	233	80	2	303
36	76	3	147	76	3	206	72	2	261
48	67	3	128	69	3	176			
60	58	4	103						

Year	2000			2001			2002		
Interval	% survival	SE	No	% survival	SE	No	% survival	SE	No
6	95	1	485	94	1	474	97	1	271
12	89	1	439	88	1	419			
24	80	2	374						

No. = number at risk SE = standard error

Figure 3.3.11: HD Technique Survival by year of entry, Private Centres
Kaplan-Meier survival estimates, by Year



**3.3.7 WORK RELATED REHABILITATION AND QUALITY OF LIFE
ON HAEMODIALYSIS, PRIVATE CENTRES**

Table 3.3.12: Work Related Rehabilitation on HD, Private centres 1999-2002

REHABILITATION STATUS	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
Full time work for pay	110	30	152	24	159	20	158	18
Part time work for pay	23	6	28	4	41	5	60	7
Able to work but unable to get a job	4	1	7	1	19	2	20	2
Able to work but not yet due to dialysis schedule	4	1	9	1	12	1	15	2
Able but disinclined to work	2	1	5	1	8	1	17	2
Home maker	86	23	173	27	191	23	200	23
Full time student	1	0	1	0	1	0	2	0
Age<15 years	0	0	0	0	0	0	0	0
Retired	46	13	79	12	111	14	134	15
Age>65 years	59	16	119	18	150	18	160	18
Unable to work due to poor health	32	9	72	11	122	15	122	14
Total	367	100	645	100	814	100	888	100

Table 3.3.13: Quality of Life on Haemodialysis, Private Centres 1999-2002

QOL Index Summated Score	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
0 (Worst QOL)	1	0	1	0	0	0	2	0
1	0	0	0	0	2	0	5	1
2	2	1	1	0	4	0	4	0
3	0	0	10	1	11	1	11	1
4	3	1	19	3	36	4	41	5
5	21	6	48	7	46	6	51	6
6	25	7	54	8	64	8	83	9
7	40	11	52	8	78	10	94	11
8	30	8	65	10	82	10	100	11
9	47	13	62	9	68	8	96	11
10 (Best QOL)	194	53	355	53	423	52	397	45
Total	363	100	667	100	814	100	884	100

3.3.8 HAEMODIALYSIS PRACTICES IN PRIVATE CENTRES

Table 3.3.14: Vascular Access on Haemodialysis, Private Centres 1999 - 2002

Access types	1999		2000		2001		2002	
	No	%	No	%	No	%	No	%
Wrist AVF	318	82	602	81	720	77	750	75
BCF*	43	11	113	15	150	16	183	18
Venous graft	4	1	3	0	7	1	4	0
Artificial graft	6	2	10	1	27	3	27	3
PERMCATH	2	1	3	0	6	1	10	1
Temporary CVC*	15	4	15	2	21	2	26	3
Total	388	100	746	100	931	100	1000	100

* BCF = Brachiocephalic fistula

* CVC = Central venous catheter

Table 3.3.15: Difficulties reported with Vascular Access, Private Centres 1999 - 2002

Access difficulty	1999		2000		2001		2002	
	No	%	No	%	No	%	No	%
Difficulty with needle placement	12	3	26	3	57	6	47	5
Difficulty in obtaining desired blood flow rate	7	2	23	3	36	4	63	6
Other difficulty	6	2	4	1	3	0	8	1
No difficulty	363	94	694	93	836	90	888	88
Total	388	100	747	100	932	100	1006	100

Table 3.3.16: Complications reported with Vascular Access, Private Centres 1999 - 2002

Complication	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
Thrombosis	10	3	22	3	39	4	59	6
Bleed	2	1	3	0	4	0	2	0
Aneurysmal dilatation	12	3	39	5	54	6	14	1
Swollen limb	6	2	3	0	5	1	11	1
Access related infection, local/Systemic	1	0	2	0	4	0	7	1
Distal Limb ischaemia	1	0	8	1	2	0	3	0
Venous outflow obstruction	1	0	6	1	14	2	10	1
Carpal tunnel	2	1	3	0	4	0	12	1
Other	6	2	5	1	11	1	22	2
No complication	347	89	656	88	796	85	866	86
Total	388	100	747	100	933	100	1006	100

Table 3.3.17: Blood Flow Rates in Private HD Units 1999 - 2002

Blood flow rates	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
<150 ml/min	1	0	2	0	5	1	2	0
150-199 ml/min	9	2	15	2	19	2	25	3
200-249 ml/min	191	53	375	52	362	40	322	33
250-299 ml/min	131	36	241	34	363	40	422	43
300-349 ml/min	23	6	78	11	159	17	182	19
> 350 ml/min	8	2	7	1	8	1	26	3
Total	363	100	718	100	916	100	979	100

Table 3.3.18: Number of HD Sessions per week, Private HD Units 1999 - 2002

HD sessions Per week	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
1	2	1	3	0	6	1	4	0
2	113	29	215	29	232	25	251	25
3	269	70	520	70	653	70	744	74
4	1	0	2	0	36	4	1	0
Total	385	100	742	100	930	100	1002	100

Table 3.3.19: Duration of HD in Private HD Units, 1999 - 2002

Duration of HD per session	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
≤3 hours	1	0	0	0	3	0	3	0
3.5 hours	8	2	9	1	11	1	0	0
4 hours	289	75	601	81	821	88	928	93
4.5 hours	51	13	68	9	45	5	29	3
5 hours	35	9	54	7	50	5	42	4
≥5 hours	0	0	10	1	0	0	0	0
Total	384	100	742	100	930	100	1002	100

Table 3.3.20: Dialyser membrane types in Private HD Units 1999 - 2002

Dialyser membrane	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
Cellulosic	141	80	316	76	330	61	211	42
Cellulose acetate	12	7	16	4	56	10	82	16
Synthetic	23	13	86	21	152	28	212	42
Total	176	100	418	100	538	100	505	100

Table 3.3.21: Dialyser Reuse Frequency in Private HD Units 1999 - 2002

Dialyser reuse frequency	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
1*	43	12	59	9	60	7	59	6
2	6	2	2	0	1	0	4	0
3	28	8	32	5	44	5	76	8
4	126	36	293	43	227	26	171	18
5	43	12	75	11	89	10	97	10
6	93	27	150	22	206	23	240	25
7	2	1	4	1	3	0	6	1
8	3	1	41	6	188	21	207	22
9	0	0	0	0	0	0	1	0
10	0	0	21	3	36	4	38	4
11	1	0	1	0	4	0	5	1
12	1	0	3	0	23	3	19	2
≥13	0	0	0	0	4	0	20	2
Total	346	100	681	100	885	100	943	100

1* is single use i.e. no reuse


Table 3.3.22: Dialysate Buffer used in Private HD Units 1999 – 2002

Dialysate buffer	1999		2000		2001		2002	
	No.	%	No.	%	No.	%	No.	%
Acetate	65	17	77	10	55	6	36	4
Bicarbonate	322	83	663	90	871	94	955	96
Total	387	100	740	100	926	100	991	100

Table 3.3.23: Distribution of Prescribed KT/V, Private Centres 1999 - 2002

Year	No of subjects	No of observations	Median	LQ	UQ	% > 1.3
1999	236	1725	1.4	1.2	1.6	61
2000	478	4584	1.4	1.2	1.7	68
2001	608	5892	1.4	1.2	1.7	65
2002	665	5914	1.5	1.3	1.7	72

Figure 3.3.23: Cumulative distribution of Prescribed KT/V by Year



3.3.9 DYSLIPIDAEMIA IN HD PATIENTS, PRIVATECENTRES

Table 3.3.24: Distribution of Serum Cholesterol Levels (mmol/L), HD patients, Private Centres 1999- 2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients < 5.3 mmol/L
1999	188	283	5.1	4.3	5.7	66
2000	339	542	4.9	4.1	5.7	66
2001	406	626	5	4.2	5.8	64
2002	494	765	4.8	4.1	5.6	71

Figure 3.3.24: Cumulative distribution of serum cholesterol concentration by year



Table 3.3.25: Distribution of serum Triglyceride (mmol/L), HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% patients < 3.5 mmol/L
1999	87	113	1.8	1.2	2.7	86
2000	254	387	1.7	1.1	2.5	86
2001	287	419	1.6	1.1	2.5	89
2002	326	485	1.9	1.3	2.6	89

Figure 3.3.25: Cumulative distribution of serum triglyceride concentration by year




Table 3.3.26: Distribution of serum LDL (mmol/L), HD patient, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% patients <5 mmol/L
1999	76	97	3	2.5	3.9	96
2000	226	340	2.9	2.2	3.5	98
2001	276	398	3	2.3	3.6	97
2002	327	474	2.7	2	3.4	98

Figure 3.3.26: Cumulative distribution of serum LDL by year





Table 3.3.27: Distribution of serum HDL (mmol/L), HD patient, Private Centres 1999 –2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients < 2mmol/L
1999	78	100	1.2	.9	1.4	95
2000	226	348	1.1	.9	1.4	94
2001	283	407	1.1	.9	1.4	93
2002	330	485	1.1	.9	1.4	96

Figure 3.3.27: Cumulative distribution of serum HDL by year



3.3.10 MANAGEMENT OF RENAL BONE DISEASE, PRIVATE CENTRES

Table 3.3.28: Treatment for Renal Bone Disease, HD patients, Private Centres 1999–2002

Year	No of subjects	% on CaCO ₃	% on Al(OH) ₃	% on Vitamin D
1999	389	82	6	30
2000	750	84	3	33
2001	933	89	2	27
2002	1015	89	2	23

Table 3.3.29: Distribution of serum Phosphate (mmol/l), HD patients, Private Centres 1999 –2002

Year	No of subjects	No of observations	Median	LQ	UQ	% patients < 1.6 mmol/L
1999	352	946	1.9	1.6	2.3	26
2000	657	1656	1.9	1.5	2.3	31
2001	780	1912	1.8	1.4	2.3	34
2002	872	2052	1.8	1.5	2.3	32

Figure 3.3.29: Cumulative distribution of serum Phosphate by year




Table 3.3.30: Distribution of serum Calcium (mmol/l), HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients ≥ 2.2 & ≤ 2.6 mmol/L
1999	353	969	2.3	2.1	2.5	52
2000	663	1687	2.3	2.2	2.5	56
2001	790	1947	2.3	2.2	2.5	60
2002	878	2101	2.3	2.1	2.5	57

Figure 3.3.30: Cumulative distribution of serum Calcium by year





Table 3.3.31: Distribution of serum iPTH (ng/L), HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% patients ≥ 100 & ≤ 250 ng/L
1999	62	85	61	22	168.8	24
2000	87	110	71	10	168	22
2001	98	133	39.3	12	142	22
2002	159	190	66.3	16	238	17

Figure 3.3.31: Cumulative distribution of serum iPTH by year,



3.3.11 MANAGEMENT OF BLOOD PRESSURE, PRIVATE CENTRES

Table 3.3.32: Treatment for hypertension, HD patients, Private Centres 1999-2002

Year	No.	% on anti-hypertensives	% on 1 anti-hypertensives	% on 2 anti-hypertensives	% on 3 anti-hypertensives
1999	389	64	39	20	6
2000	750	66	41	21	5
2001	933	68	41	23	5
2002	1015	67	38	24	5

Table 3.3.33: Distribution of Systolic BP without anti-hypertensives, HD patients Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients < 160 mmHg
1999	131	833	142	130	160	69
2000	244	2287	140	125	160	73
2001	287	2633	140	120	151	80
2002	328	2704	140	128	160	73

Figure 3.3.33: Cumulative distribution of Systolic BP without anti-hypertensives by year




Table 3.3.34: Distribution of Diastolic BP without anti-hypertensives, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients < 90 mmHg
1999	131	835	80	73	90	67
2000	244	2287	80	70	87	77
2001	287	2639	80	70	83	82
2002	328	2705	80	70	88	77

Figure 3.3.34: Cumulative distribution of Diastolic BP without anti-hypertensives by year




Table 3.3.35: Distribution of systolic BP on anti-hypertensives, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients < 160 mmHg
1999	246	1838	153	140	170	53
2000	482	4392	156	140	171	52
2001	631	5879	155	140	172	53
2002	659	5389	156	140	170	52

Figure 3.3.35: Cumulative distribution of systolic BP on anti-hypertensives by year





Table 3.3.36: Distribution of diastolic BP on anti-hypertensives, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients < 90 mmHg
1999	246	1839	84	80	90	56
2000	482	4394	83	76	90	59
2001	631	5880	81	74	90	61
2002	658	5386	80	73	90	62

Figure 3.3.36: Cumulative distribution of diastolic BP on anti-hypertensives by year



3.3.12 TREATMENT OF ANAEMIA, PRIVATE HD CENTRES

Table 3.3.37: Treatment for Anaemia, HD patients, Private Centres 1999-2002

Year	No	% on rHuEpo	% received blood transfusion	% received oral iron	% received parenteral iron
1999	389	60	23	81	13
2000	750	64	20	75	3
2001	933	66	20	80	5
2002	1015	68	17	75	4

Table 3.3.38: Distribution of rHuEpo dose per week, HD patients, Private Centres 1999-2002

Year	1999	2000	2001	2002
No. of patients	225	464	595	645
% on 2000 u/week	29	31	29	33
% on 2-4000 u/week	62	58	54	56
% on 4-6000 u/week	4	7	11	8
% on 6-8000 u/week	3	2	2	2
% on 8-12000 u/week	2	2	3	1
% on >12000 u/week	0	0	1	0

Table 3.3.39: Distribution of serum Iron without rHuEpo, HD patients, PrivateCentres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients > 10 umol/L
1999	16	26	10.9	9.1	14.4	58
2000	28	45	12.2	9	17.1	64
2001	27	40	14.6	10	21	73
2002	24	39	12	6	19.4	54

Figure 3.3.39: Cumulative distribution of serum Iron without rHuEpo by year




Table 3.3.40: Distribution of serum Iron on rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients > 10 $\mu\text{mol/L}$
1999	67	85	12.7	9.1	18.3	69
2000	62	84	13.1	9.1	21.1	67
2001	95	108	13.9	9.6	17.9	72
2002	134	157	12.2	8.4	18.8	61

Figure 3.3.40: Cumulative distribution of serum Iron on rHuEpo by year




Table 3.3.41: Distribution of serum Transferrin Saturation without rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients > 20%
1999	9	36	25.1	19.1	29.7	67
2000	24	96	23.6	16.9	35.7	63
2001	21	84	38	25.6	60.1	76
2002	15	60	23.3	14.2	36.6	67

Figure 3.3.41: Cumulative distribution of serum Transferrin Saturation without rHuEpo by year




Table 3.3.42: Distribution of serum Transferrin Saturation on rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients > 20%
1999	43	172	31.6	21.6	49.8	84
2000	52	208	35.2	23.3	52.1	83
2001	89	356	32.6	21.8	47	79
2002	82	328	29.4	20.6	47.2	76

Figure 3.3.42: Cumulative distribution of serum Transferrin Saturation on rHuEpo by year




Table 3.3.43: Distribution of serum Ferritin without rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients > 100 ug/L
1999	21	27	323	90	776	70
2000	31	46	284.6	122	463.7	83
2001	33	45	403	176	831	84
2002	32	45	464.1	228.1	993.7	87

Figure 3.3.43: Cumulative distribution of serum Ferritin without rHuEpo by year




Table 3.3.44: Distribution of serum Ferritin on rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% patients > 100 ug/L
1999	106	149	476.4	309	876	95
2000	105	142	508	229	978	92
2001	158	211	566	288	926	91
2002	172	208	554	256.1	997.5	91

Figure 3.3.44: Cumulative distribution of serum Ferritin on rHuEpo by year




Table 3.3.45: Distribution of Haemoglobin concentration without rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients <10 g/dL	% Patients ≥ 10 & ≤ 12 g/dL	% Patients >12 g/dL
1999	139	381	8.7	7.7	10.3	70	20	10
2000	241	620	8.8	7.6	10.3	70	22	8
2001	257	627	8.9	7.7	10.2	69	22	9
2002	266	627	9	7.7	10.5	66	22	12

Figure 3.3.45: Cumulative distribution of Hb without rHuEpo by year





Table 3.3.46: Distribution of haemoglobin concentration on rHuEpo, HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients <10 g/dL	% Patients ≥ 10 & ≤ 12 g/dL	% Patients >12 g/dL
1999	219	687	9.4	8.2	10.6	64	30	6
2000	452	1331	9.2	8	10.5	65	28	6
2001	566	1584	9.4	8.4	10.6	61	32	8
2002	633	1692	9.6	8.4	10.9	55	35	10

Figure 3.3.46: Cumulative distribution of Haemoglobin on rHuEpo by year



3.3.13 NUTRITIONAL STATUS OF HD PATIENTS PRIVATE CENTRES

Table 3.3.47: Distribution of serum Albumin (g/L), HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients >40g/L
1999	288	798	37	34	41	31
2000	504	1227	37	35	40.6	32
2001	668	1655	37	34	39	22
2002	756	1694	38	35	41	35

Figure 3.3.47: Cumulative distribution of serum Albumin by year





Table 3.3.48: Distribution of Body Mass Index HD patients, Private Centres 1999-2002

Year	No of subjects	No of observations	Median	LQ	UQ	% Patients <18.5	% Patients ≥ 18.5 & ≤ 25	% Patients >25
1999	272	1917	21.6	19.4	24.5	14	64	22
2000	567	5440	21.6	19.4	24.6	17	60	22
2001	689	6684	21.8	19.3	25	18	57	25
2002	639	5571	21.9	19.5	24.8	16	61	23

Figure 3.3.48: Cumulative distribution of body mass index by year



3.3.14 SEROLOGICAL STATUS, HD PATIENTS PRIVATECENTRES

Table 3.3.49: Prevalence of positive anti-HCV antibody and HbsAg, HD patients, Private Centres 1999-2002

Year	No	% HBsAg positive	% anti-HCV positive
1999	389	4	17
2000	750	4	24
2001	933	4	23
2002	1015	3	26

Figure 3.3.49: Prevalence of positive anti-HCV antibody and HbsAg HD patients, Private Centres 1999 – 2002

